TW202227397A - 雙環的－雜環衍生物及相關用途 - Google Patents
雙環的－雜環衍生物及相關用途 Download PDFInfo
- Publication number
- TW202227397A TW202227397A TW110132883A TW110132883A TW202227397A TW 202227397 A TW202227397 A TW 202227397A TW 110132883 A TW110132883 A TW 110132883A TW 110132883 A TW110132883 A TW 110132883A TW 202227397 A TW202227397 A TW 202227397A
- Authority
- TW
- Taiwan
- Prior art keywords
- alkyl
- alkenyl
- cycloalkyl
- alkynyl
- aryl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/54—Spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063074216P | 2020-09-03 | 2020-09-03 | |
| US63/074,216 | 2020-09-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202227397A true TW202227397A (zh) | 2022-07-16 |
Family
ID=78078375
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110132883A TW202227397A (zh) | 2020-09-03 | 2021-09-03 | 雙環的－雜環衍生物及相關用途 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US12503475B2 (enExample) |
| EP (1) | EP4208444A1 (enExample) |
| JP (1) | JP7840517B2 (enExample) |
| CN (1) | CN116583502A (enExample) |
| TW (1) | TW202227397A (enExample) |
| WO (1) | WO2022051596A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016057931A1 (en) | 2014-10-10 | 2016-04-14 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| US12006330B2 (en) | 2020-12-21 | 2024-06-11 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| JP7833486B2 (ja) | 2021-05-26 | 2026-03-19 | アルカーメス，インコーポレイテッド | 置換されるカルバメート大環状化合物および関連のある治療方法 |
| CN119156375A (zh) * | 2022-03-01 | 2024-12-17 | 森特萨制药(英国)有限公司 | 双环杂环衍生物和相关用途 |
| CN115124410B (zh) * | 2022-08-13 | 2024-06-04 | 上海珂华生物科技有限公司 | 一种2-氟-4-羟基苯甲醛的制备方法 |
| TW202432109A (zh) | 2022-10-31 | 2024-08-16 | 日商武田藥品工業股份有限公司 | 食慾素２型受體促效劑之給藥 |
| JPWO2024128305A1 (enExample) | 2022-12-16 | 2024-06-20 | ||
| TW202502342A (zh) | 2023-06-02 | 2025-01-16 | 日商武田藥品工業股份有限公司 | 食慾素２受體促效劑用於改善睡眠期間之呼吸功能的用途 |
| CN122374291A (zh) | 2023-12-12 | 2026-07-10 | 爱杜西亚药品有限公司 | 作为食欲素受体调节剂的芳基砜及砜酮衍生物 |
| WO2025132542A1 (en) | 2023-12-19 | 2025-06-26 | Idorsia Pharmaceuticals Ltd | Macrocyclic orexin agonists |
| WO2025137359A1 (en) * | 2023-12-20 | 2025-06-26 | Eisai R&D Management Co., Ltd. | Assay methods to identify a disease |
| GB202404750D0 (en) | 2024-04-03 | 2024-05-15 | Bial Portela & Ca Sa | Orexin receptor agonists |
| WO2025229493A1 (en) | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Dosing of orexin type 2 receptor agonists |
| WO2025229495A1 (en) * | 2024-04-29 | 2025-11-06 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| KR20260012686A (ko) * | 2024-07-18 | 2026-01-27 | (주)셀트리온 | 신규한 오렉신 2 수용체 작용제 및 이의 용도 |
| WO2026114912A1 (en) | 2024-11-27 | 2026-06-04 | H. Lundbeck A/S | Orexin 2 receptor agonists |
| WO2026114911A1 (en) | 2024-11-27 | 2026-06-04 | H. Lundbeck A/S | Orexin 2 receptor agonists |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5763263A (en) | 1995-11-27 | 1998-06-09 | Dehlinger; Peter J. | Method and apparatus for producing position addressable combinatorial libraries |
| WO2008076415A1 (en) | 2006-12-14 | 2008-06-26 | Exelixis, Inc. | Methods of using mek inhibitors |
| CA2684169C (en) | 2007-04-12 | 2012-06-19 | Joyant Pharmaceuticals, Inc. | Smac mimetic dimers and trimers useful as anti-cancer agents |
| US8030307B2 (en) | 2007-11-29 | 2011-10-04 | Enanta Pharmaceuticals, Inc. | Bicyclic, C5-substituted proline derivatives as inhibitors of the hepatitis C virus NS3 protease |
| US8871794B2 (en) | 2008-06-04 | 2014-10-28 | Board Of Regents, The University Of Texas System | Small-molecule agonists for type-2 orexin receptor |
| US20100074863A1 (en) | 2008-09-17 | 2010-03-25 | Yat Sun Or | Anti-infective pyrrolidine derivatives and analogs |
| EP2275421A1 (en) * | 2009-07-15 | 2011-01-19 | Rottapharm S.p.A. | Spiro amino compounds suitable for the treatment of inter alia sleep disorders and drug addiction |
| NO2513053T3 (enExample) | 2009-12-18 | 2018-03-03 | ||
| GB201103526D0 (en) | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
| EP2763532B1 (en) | 2011-10-05 | 2018-09-19 | The Board of Trustees of the Leland Stanford Junior University | Pi-kinase inhibitors with broad spectrum anti-infective activity |
| ITMI20112329A1 (it) * | 2011-12-21 | 2013-06-22 | Rottapharm Spa | Nuovi derivati spiro amminici |
| CN105916500A (zh) | 2013-11-27 | 2016-08-31 | 欧洲筛选有限公司 | 用于治疗炎性疾病的化合物、药物组合物和方法 |
| MA40404A (fr) | 2014-08-05 | 2017-06-14 | Alios Biopharma Inc | Polythérapie pour traiter un paramyxovirus |
| WO2016021629A1 (ja) | 2014-08-06 | 2016-02-11 | 塩野義製薬株式会社 | ＴｒｋＡ阻害活性を有する複素環および炭素環誘導体 |
| SG11201806429PA (en) | 2016-02-04 | 2018-08-30 | Takeda Pharmaceuticals Co | Substituted piperidine compound and use thereof |
| JP7012703B2 (ja) | 2017-03-08 | 2022-02-14 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| JP6957598B2 (ja) | 2017-03-08 | 2021-11-02 | 武田薬品工業株式会社 | 置換ピロリジン化合物およびその用途 |
| US10428023B2 (en) * | 2017-08-03 | 2019-10-01 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and use thereof |
| WO2019027069A1 (ko) * | 2017-08-03 | 2019-02-07 | (주)상아프론테크 | 연료전지 전해질 강화막 및 이의 제조방법 |
| EP3816154B1 (en) | 2018-06-29 | 2025-04-23 | Takeda Pharmaceutical Company Limited | Heterocyclic compound and application thereof |
| JP7408569B2 (ja) | 2018-12-12 | 2024-01-05 | 武田薬品工業株式会社 | 複素環化合物 |
| JP7379374B2 (ja) | 2018-12-12 | 2023-11-14 | 武田薬品工業株式会社 | 複素環化合物 |
| PE20211700A1 (es) * | 2019-01-31 | 2021-09-01 | Takeda Pharmaceuticals Co | Compuesto heterociclico y su uso |
| US11098029B2 (en) | 2019-02-13 | 2021-08-24 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
| JP2022547604A (ja) | 2019-09-13 | 2022-11-14 | 武田薬品工業株式会社 | 過度の眠気の治療のためのオレキシン２受容体アゴニストの使用 |
| WO2021048822A1 (en) | 2019-09-13 | 2021-03-18 | Takeda Pharmaceutical Company Limited | Tak-925 for use in treating narcolepsy |
| JPWO2021065893A1 (enExample) | 2019-09-30 | 2021-04-08 | ||
| KR20260083444A (ko) | 2019-11-25 | 2026-06-05 | 알케르메스,인코포레이티드 | 치환된 마크로사이클릭 화합물 및 관련 치료 방법 |
| PE20221730A1 (es) | 2019-11-27 | 2022-11-07 | Sumitomo Pharma Co Ltd | Derivado de cicloalquilurea |
| US20210200298A1 (en) | 2019-12-30 | 2021-07-01 | Advanced Micro Devices, Inc. | Long-idle state system and method |
| US12503475B2 (en) | 2020-09-03 | 2025-12-23 | Centessa Pharmaceuticals (Uk) Limited | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists |
| CN116635393A (zh) | 2020-09-03 | 2023-08-22 | 欧瑞夏治疗有限公司 | 中环或大环苄基取代的杂环衍生物及其作为食欲素-2受体激动剂的用途 |
| WO2022207935A1 (en) | 2021-04-02 | 2022-10-06 | Orexia Therapeutics Limited | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists |
| WO2023017180A1 (en) | 2021-08-13 | 2023-02-16 | Orexia Therapeutics Limited | Peptide derivatives and related uses as orexin agonists |
| CN119156375A (zh) | 2022-03-01 | 2024-12-17 | 森特萨制药(英国)有限公司 | 双环杂环衍生物和相关用途 |
| WO2023167925A1 (en) | 2022-03-01 | 2023-09-07 | Orexia Therapeutics Limited | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses |
-
2021
- 2021-09-03 US US18/024,216 patent/US12503475B2/en active Active
- 2021-09-03 CN CN202180074263.5A patent/CN116583502A/zh active Pending
- 2021-09-03 JP JP2023515057A patent/JP7840517B2/ja active Active
- 2021-09-03 EP EP21786660.7A patent/EP4208444A1/en active Pending
- 2021-09-03 TW TW110132883A patent/TW202227397A/zh unknown
- 2021-09-03 WO PCT/US2021/049021 patent/WO2022051596A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022051596A8 (en) | 2022-04-07 |
| EP4208444A1 (en) | 2023-07-12 |
| CN116583502A (zh) | 2023-08-11 |
| WO2022051596A1 (en) | 2022-03-10 |
| JP7840517B2 (ja) | 2026-04-06 |
| US20230271973A1 (en) | 2023-08-31 |
| US12503475B2 (en) | 2025-12-23 |
| JP2023540344A (ja) | 2023-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12503475B2 (en) | Bicyclic-heterocycle derivatives and their uses as orexin-2 receptor agonists | |
| TW202227433A (zh) | 中環或大環之經苄基取代的雜環衍生物及相關用途 | |
| CN101687827B (zh) | 环状基团取代的氨基二氢噻嗪衍生物 | |
| CN105814050B (zh) | 用作tnf活性调节剂的吡唑并吡啶衍生物 | |
| CN111801318B (zh) | 受体抑制剂、包含其的药物组合物及其用途 | |
| CN105814053B (zh) | 作为tnf活性调节剂的咪唑并吡啶衍生物 | |
| CN110267962A (zh) | Magl抑制剂 | |
| TW201734001A (zh) | ＲＯＲ－γ調節劑 | |
| WO2022207935A1 (en) | 2-(3-ethynylbenzyl)-substituted heterocycle derivatives as orexin-2 agonists | |
| WO2018167176A1 (en) | Fused pentacyclic imidazole derivatives as modulators of tnf activity | |
| WO2023167865A1 (en) | Bicyclic-heterocycle derivatives and related uses | |
| AU2023228830A1 (en) | Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and related uses | |
| TW202317092A (zh) | Ｋｉｆ１８ａ之吲哚啉抑制劑 | |
| TW202134248A (zh) | Sstr5拮抗劑 | |
| CN119403794A (zh) | 用于治疗trpm3介导的病症的新型衍生物 | |
| CN111902401B (zh) | 受体抑制剂、包含其的药物组合物及其用途 | |
| WO2021228216A1 (zh) | 可用作RORγ调节剂的联芳基类化合物 | |
| WO2021228215A1 (zh) | 可用作RORγ调节剂的联芳基类化合物 | |
| CN119490501A (zh) | 咪唑双环化合物及其制备方法和用途 | |
| CN117945945A (zh) | 一种gpr139受体激动剂、其制备方法及其应用 | |
| HK40119559A (en) | Compounds and compositions for treating conditions associated with lpa receptor activity | |
| JP2025537627A (ja) | セレン含有複素環式化合物およびその使用 | |
| WO2026002203A1 (zh) | 组织蛋白酶c抑制剂化合物及其应用 |